Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idelalisib + obinutuzumab in relapsed or refractory follicular lymphoma
2018-001229-18Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib and obinutuzumab in follicular lymphoma (FL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Clinical response. Started Jun 2021; status: completed.
02
Drugs
idelalisibobinutuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on 2018-001229-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001229-18.